StreetAlpha.app
Home › Stocks › AQST

Aquestive Therapeutics, Inc. (AQST)

Healthcare
$3.46
▼ −6.61%
LAST CLOSE · NOV 20

Aquestive develops oral film drug delivery technology and medicines for patients and pharmaceutical partners. It last closed at $3.46 on Nov 20, down 6.61% on the day. The next earnings report for AQST is expected around Wed, Mar 3, 2027, after the close. For the quarter ended Sep 2026, AQST reported EPS of -$0.13 on revenue of $7.6M, with revenue down 41.0% from a year ago. Over its last 8 reports the stock moved an average of 6.8% the session after earnings. Over the last 12 months AQST insiders bought $99K of stock on the open market and sold $2.4M, according to SEC Form 4 filings.

AI Auto Pilots
Is AQST in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold AQST.

Key Stats

Last 12 months
Results
Revenue
$48.8M
+12.5% vs a year ago
Net income
−$79.3M
−162.3% margin
EPS (diluted)
−$0.65
Free cash flow
−$40.7M
−83.3% margin
Valuation
Market cap
$434.9M
125.7M shares
P/E
–
No P/E while losing money
Price to sales
8.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$90.3M
At Sep 30
Debt
$55.0M
At Sep 30
Shareholder equity
−$70.8M
Shares outstanding
125.7M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $50.8M$50.8MFY2021FY2022: $47.7M$47.7MFY2022FY2023: $50.6M$50.6MFY2023FY2024: $57.6M$57.6MFY2024FY2025: $44.5M$44.5MFY2025

From AQST's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Mar 3
Estimated date · After the close
Reported EPS
-$0.13
Quarter ended Sep 2026
Year ago EPS
-$0.14
Same quarter last year
Revenue
$7.6M
−41.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.19Dec '24Mar 2025: -$0.24Mar '25Jun 2025: -$0.14Jun '25Sep 2025: -$0.14Sep '25Dec 2025: -$0.27Dec '25Mar 2026: -$0.07Mar '26Jun 2026: -$0.18Jun '26Sep 2026: -$0.13Sep '26Latest -$0.13
Revenue by quarter
Dec 2024: $11.9MDec '24Mar 2025: $8.7MMar '25Jun 2025: $10.0MJun '25Sep 2025: $12.8MSep '25Dec 2025: $13.0MDec '25Mar 2026: $14.4MMar '26Jun 2026: $13.8MJun '26Sep 2026: $7.6MSep '26Latest $7.6M
How AQST moved after its last 8 reports
Average move the session after a report ±6.8%
Nov 3, 2026After the close−2.1%
Aug 11, 2026After the close−4.1%
May 13, 2026After the close+14.5%
Mar 4, 2026After the close−2.5%
Nov 5, 2025After the close+2.2%
Aug 11, 2025After the close−2.1%
May 12, 2025After the close−19.6%
Mar 5, 2025After the close−7.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on AQSTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on AQST
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on AQST

Technical Analysis

AQST · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 9% below its 20 day and 22% below its 50 day average. It is 22% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 36), near oversold. The nearest support is the swing low (Nov 9) at $3.37, and the nearest resistance the Pivot at $3.51.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 6.9%/day
Key levels
$6.7452 week high+94.8%
$4.30100 day average+24.3%
$4.2350 day average+22.3%
$4.22200 day average+22.0%
$3.96Swing high (Nov 13)+14.5%
$3.7720 day average+9.0%
$3.61Pivot R1+4.3%
$3.51Pivot+1.4%
$3.46Last close
$3.37Swing low (Nov 9)−2.6%
$3.36Pivot S1−2.9%
$2.9352 week low−15.3%
Indicators
RSI (14)36.29Weak, oversold below 30Neutral
MACD-0.17Above its signal lineBullish
Stochastic41.1Middle of its rangeNeutral
ADX (14)22.8Weak trend
Williams %R-86.7Oversold below −80, overbought above −20Oversold
CCI (20)-124.0Oversold below −100, overbought above 100Oversold
Rate of change−4.2%Change over 10 sessionsBearish
ATR (14)$0.24Typical daily range, 6.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AQST

What happened before

See how AQST did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow AQST usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How AQST has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for AQSTHow many large options trades hit AQST, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

AQST Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲90 buying vs 78 selling
  • ▲Held by funds +2.9 pts
  • ▲Funds holding +5
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding191186+2.7%
In funds' top 1032+50.0%
Held by funds60.2%57.3%+2.9 pts
New / increased24 / 6623 / 670.0%
Reduced / sold out57 / 2145 / 21+18.2%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AQST institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AQST Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$99K1 buy · 1 insider
Sold$2.4M16 sales · 9 insiders
32% of the selling was under pre-arranged trading plans.
2026-03 sold $1.7M2026-05 sold $35K2026-06 sold $229K2026-07 sold $100K2026-08 sold $107K2026-09 sold $166K2026-10 sold $106K2026-11 bought $99K2026-11 sold $26KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 12Matthew W. DavisChief Development OfficerSale plan7,197$3.55$26K
Nov 10Richard J DalyDirectorBuy28,025$3.54$99K
Oct 15Daniel BarberPresident and CEOSale plan25,000$4.22$106K
Sep 15Daniel BarberPresident and CEOSale plan25,000$4.82$120K
Sep 9Sherry KorczynskiChief Commercial OfficerSale plan8,750$5.22$46K
Aug 17Daniel BarberPresident and CEOSale plan25,000$4.29$107K
Every insider buy and sale for AQST over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See AQST insider trades →

From SEC Form 4 filings by AQST's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AQST is in one of them and how their past AQST trades turned out.

AQST in the AI portfolios
Loading…

AQST News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AQST in an article yet. Here's the latest on the wider market.

AQST in the news

About Aquestive Therapeutics

Aquestive Therapeutics is a pharmaceutical company that develops medicines using oral film and other drug delivery technologies. Its PharmFilm product is a thin film that dissolves in the mouth, and it is used to deliver prescription medicines. The company is developing Anaphylm, an epinephrine treatment for severe allergic reactions that dissolves under the tongue. It also manufactures licensed products that partner companies sell to patients and physicians. Aquestive is headquartered in Warren, New Jersey, and produces its products at a facility in Portage, Indiana.

Headquarters
Warren, NJ